The FDA has since said it is reviewing its decision. Last week, Novo Nordisk (NVO) asked the FDA to have semaglutide placed on the Demonstrable Difficulties for Compounding List, arguing that ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Semaglutide is the key ingredient in Novo Nordisk A/S’s (NYSE:NVO) popular drugs, including Wegovy for weight loss and Ozempic for diabetes. Tuesday, Novo Nordisk’s FLOW kidney outcomes trial ...

Novo Nordisk's late stage diabetes candidate semaglutide has scored another victory, outperforming Eli Lilly’s Trulicity in controlling glucose levels and body weight. The phase 3 trial success ...

Novo Nordisk has shared positive headline results from a late-stage study evaluating a higher dose of its GLP-1 receptor agonist semaglutide in adults with obesity. The phase 3b STEP UP trial has been ...

Detailed results from Novo's trial testing the higher dose of Wegovy, which contains the active ingredient semaglutide, are expected to be presented at a scientific conference in 2025, according ...

Novo Nordisk's high dose Wegovy (semaglutide) has shown improved weight loss while remaining safe and tolerable. In the Phase IIIb STEP UP trial, 7.2mg Wegovy demonstrated statistically ...